1. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections
- Author
-
Adam P. Roberts, Andrew C. Singer, and Claas Kirchhelle
- Subjects
0301 basic medicine ,antibiotic resistance ,drug pipeline ,Drug Industry ,International Cooperation ,qv_38 ,Intellectual property ,Communicable Diseases ,antibiotics ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Drug Discovery ,Drug Resistance, Bacterial ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,Drug pipeline ,wb_330 ,Pharmaceutical industry ,Finance ,General Immunology and Microbiology ,qv_4 ,business.industry ,qs_4 ,Articles ,General Medicine ,Opinion Article ,Investment (macroeconomics) ,Antimicrobial ,Intellectual Property ,Anti-Bacterial Agents ,3. Good health ,Biology and Microbiology ,030104 developmental biology ,Incentive ,Biopharmaceutical ,antimicrobial ,Medicine ,business ,030217 neurology & neurosurgery - Abstract
Opinion article. The pipeline for new antibiotics is dry. Despite the creation of public/private initiatives like Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) and the Antimicrobial Resistance (AMR) Centre, the current focus on ‘push-pull’ incentives for the pharmaceutical industry still relies on economic return. We propose a joint, internationally-funded antimicrobial development institute that would fund permanent staff to take on roles previously assigned to pharmaceutical companies. This institute would receive ring-fenced, long-term, core funding from participating countries as well as charities, with the aim to focus on transforming the largely dormant antimicrobial pipeline. Resulting drugs would be sold globally and according to a principle of shared burdens. Our proposed model for antimicrobial development aims to maximise society’s investment, through open science, investment in people, and the sharing of intellectual property.
- Published
- 2019